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abstract
PURPOSE The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of
young patients. An attenuated dose of chemotherapy—cyclophosphamide, doxorubicin, vincristine, and
prednisone plus rituximab (R-miniCHOP)—is a good compromise between efficacy and safety in very elderly
patients. In combination with R-CHOP (R2-CHOP), lenalidomide has an acceptable level of toxicity and may
mitigate the negative prognosis of the non–germinal center B-cell–like phenotype. The Lymphoma Study
association conducted a multicentric, phase III, open-label, randomized trial to compare R-miniCHOP and R2-
miniCHOP.
PATIENTS AND METHODS Patients of age 80 years or older with untreated DLBCL were randomly assigned into
the R-miniCHOP21 group or the R2-miniCHOP21 group for six cycles and stratified according to CD10 ex-
pression and age. The first cycle of rituximab was delivered by IV on D1 after a prephase and then delivered
subcutaneously on D1 of cycles 2-6. Lenalidomide was delivered at a dose of 10 mg once daily on D1-D14 of
each cycle. The primary end point was overall survival (OS).
RESULTS A total of 249 patients with new DLBCL were randomly assigned (127 R-miniCHOP and 122 R2-
miniCHOP). The median age was 83 years (range, 80-96), and 55% of the patients were classified as non-GCB.
The delivered dose for each R-miniCHOP compound was similar in both arms. Over a median follow-up of
25.1 months, the intention-to-treat analysis revealed that R2-miniCHOP did not improve OS (2-year OS 66% in
R-miniCHOP and 65.7% in R2-miniCHOP arm, P5 .98) in the overall population or in the non-GCB population.
Grade 3-4 adverse events occurred in 53% of patients with R-miniCHOP and in 81% of patients with R2-
miniCHOP.
CONCLUSION The addition of lenalidomide to R-miniCHOP does not improve OS. Rituximab delivered sub-
cutaneously was safe in this population.
J Clin Oncol 00. © 2021 by American Society of Clinical Oncology
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most
common lymphoma subtype, and its incidence steadily
increases with age. Approximately 40% of patients with
DLBCL are older than 70 years. Despite the develop-
ment of the anti-CD20 antibody in combination with
chemotherapy, the prognosis of elderly patients with
newly diagnosed DLBCL is worse than that of young
patients. Comorbidities and physiological organ func-
tion impairment often lead to unmanageable toxicities
and limit optimal chemotherapy. An attenuated dose
of chemotherapy (cyclophosphamide, doxorubicin,
vincristine, and prednisone, referred to as mini-CHOP)
with a conventional dose of anti-CD20, that is, rituximab
(R) or ofatumumab, has been evaluated by the LYSA
group in two phase II trials and is considered a good
compromise between efficacy and safety in patients
older than 80 years.1-3 In this setting, the 2-year overall
survival (OS) varied from 59% to 65%. Toxicities were
manageable, as most events occurred during the first
two cycles. A prephase containing a short course of
vincristine and prednisone eventually improves out-
come in this frail population.1,4-6 Although there is no
specific histological DLBCL subtype in very elderly
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frequency of the two main molecular–defined subtypes,
namely, germinal center B-cell–like (GCB) and activated
B-cell–like (ABC) subtypes, differs according to patient age.
Additionally, an increase in the ABC subtype prevalence
during the aging of patients with DLBCL has been widely
reported, even if its clinical and prognostic relevance among
patients older than 80 years remains unclear.7 Many strat-
egies have been proposed to more specifically target the
ABC DLBCL subtype and attenuate its unfavorable outcome.
Lenalidomide is an oral immunomodulatory drug with
complex and pleiotropic immunologic and antiproliferative
activities in B-cell lymphomas.8 Lenalidomide demonstrated
activity in xenograft models of ABC DLBCL by down-
regulating the BCR-NFKB pathway through inhibition of
IRF4 and Cereblon.9 In combination with R-CHOP (R2-
CHOP), lenalidomide has acceptable levels of toxicity and
may mitigate the negative prognosis of the non-GCB
phenotype.7,10-14 It has also been suggested that the clini-
cal benefit of lenalidomide monotherapy in patients with
DLBCL was more evident in the gene-expression profiling
(GEP)–defined ABC population.15 On the basis of these data,
we designed a randomized phase III clinical trial to deter-
mine the tolerance and efficacy of the R2-miniCHOP regi-
men in comparison to R-miniCHOP in patients older than 80
years with newly diagnosed DLBCL.
PATIENTS AND METHODS
Study Design and Patients
SENIOR is a multicentric, phase III, open-label, random-
ized trial for patients of age 80 years or older with previously
untreated CD20 1 DLBCL. Eligibility criteria included
stages II-IV, measurable disease, a revised International
Prognostic Index (IPI) score of 1 or higher, and an Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) of 2 or lower. The exclusion criteria were known CNS
lymphoma or meningeal involvement, cardiac dysfunction
assessed by isotopic or echotomographic measure, or renal
insufficiency assessed by creatinine clearance lower than
40 mL/min (minimal residual disease).
Eligible patients were randomly assigned 1:1 to standard
R-miniCHOP or R2-miniCHOP on a 21-day cycle for six cy-
cles. Patients were stratified in each arm according to CD10
expression (local assessment with a threshold of positivity of
30%) and age (# 85 years or. 85 years). Patients provided
written informed consent before enrollment. This study was
approved by an independent research ethics committee and
performed in accordance with the International Conference
on Harmonization Good Clinical Practice Guidelines, the
Declaration of Helsinki (1996), and local regulatory require-
ments and laws. An independent Data and Safety Monitoring
Committee (DSMC) reviewed safety and risk and/or benefit
throughout the clinical trial at planned intervals.
Treatment Procedure
All patients received prephase treatment with vincristine
(1 mg total dose given once intravenously 1 week before
cycle 1 [day 2 7]) and oral prednisone (60 mg/m2 once
daily total dose, days2 7 to2 1) before the first cycle of R/
R2-miniCHOP. R-MiniCHOP consisted of rituximab
375 mg/m2 intravenously once on day 1 and then
1,400 mg total dose subcutaneously once on day 1 of
cycles 2-6, 25 mg/m2 once on day 1 of doxorubicin,
400 mg/m2 once on day 1 of cyclophosphamide, and 1mg
once on day 1 of vincristine, and 40 mg/m2 of oral
prednisone once daily on days 1-5. Lenalidomide was
given at a dose of 10 mg once daily TD on D1 to D14 every
3 weeks with venous thrombosis prophylaxis (aspirin or
low-molecular-weight heparin; Data Supplement, online
only).
Cell of Origin Classification
Available tumor samples were retrospectively classified for
the cell of origin (COO) subtypes (namely, GCB, ABC, and
unclassified) by central laboratory GEP of formalin-fixed
paraffin-embedded biopsy tissue using Lymph2CX assay
CONTEXT
Key Objective
How to improve the current standard attenuated dose of immunochemotherapy (cyclophosphamide, doxorubicin, vin-
cristine, and prednisone plus rituximab [R-mini-CHOP]) to treat patients older than 80 years with newly diagnosed diffuse
large B-cell lymphoma (DLBCL)?
Knowledge Generated
The addition of lenalidomide to R (sub/cutaneous)-miniCHOP schema does not improve overall survival (OS) irrespective of
germinal center B-cell–like/activated B-cell–like status and results in more adverse events. Albuminemia is, with staging,
the most significant factor related to OS, independent of the International Prognostic Index and geriatric scales.
Relevance
Rituximab delivered subcutaneously with miniCHOP remains a gold standard in very elderly patients with DLBCL and led to
a 2-year OS of 66%. Albuminemia can be used as a simple and strong prognostic marker.
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(NanoString Technologies, Seattle, WA).16 Hans-based
immunohistochemistry (IHC) classification (CD10, BCL6,
and MUM1) was retrospectively performed by the central
review platform to define GCB and non-GCB subtypes17.
Primary and Secondary End Points and Assessments
Primary efficacy analyses were conducted in the intention-
to-treat (ITT) population, defined as all patients who were
randomly assigned, regardless of whether they received
treatment. The primary end point was OS. Secondary end
points were progression-free survival (PFS), event-free
survival (EFS), duration of response (DOR) for complete
responders and unconfirmed complete responders (CR/
CRu), response rate at the end of the treatment, and the
differential efficacy of the R2-miniCHOP according to the
GCB/non-GCB IHC phenotype.
TABLE 1. Clinical and Biological Features of the SENIOR Cohort
Characteristic
R-miniCHOP
n 5 127 (%)
R2-miniCHOP
n 5 122 (%)
Total
N 5 249 (%)
Sex
Male 56 (44) 57 (46) 113 (45)
Age (year)
80-85 95 (75) 93 (76) 188 (75.5)
. 85 32 (25) 29 (24) 61 (24.5)
Ann Arbor stage
I-II 22 (17) 16 (13) 38 (15)
III-IV 105 (83) 106 (87) 211 (85)
Performance status (ECOG)
0-1 91 (72) 95 (78) 186 (75)
2 36 (28) 27 (22) 63 (25)
IPI
Missing 1 3 4
0-2 32 (25) 33 (28) 65 (26.5)
3-5 94 (75) 86 (72) 180 (73.5)
CD10 expression (IHC)
Negative 79 (62) 79 (65) 158 (63.5)
Positive 48 (38) 43 (35) 91 (36.5)
Phenotype (Hans algorithm)
GCB 41 (40) 54 (50) 95 (45)
Non-GCB 62 (60) 55 (50) 117 (55)
Missing data 24 13 37
Phenotype (Lymph2CX)
GCB or unclassified 39 (50) 44 (58) 83 (54)
ABC 38 (50) 33 (42) 71 (46)
Missing data 50 45 95
MYC expression (IHC) 41/72 (57) 45/76 (59) 86/148 (58)
BCL2 expression (IHC) 90/100 (90) 90/102 (89) 180/202 (89)
MYC or BCL2 double expressor 39/68 (57) 40/70 (57) 79/138 (57)
MYC rearrangement (FISH) 9/83 (11) 13/86 (15) 22/169 (13)
BCL2 rearrangement (FISH) 19/83 (23) 16/82 (19) 35/165 (21)
BCL6 rearrangement (FISH) 21/85 (25) 18/83 (21) 39/168 (23)
Double or triple hits (FISH) 6/116 (5) 5/118 (4) 11/223 (5)
NOTE. BCL2/MYC protein expression was determined according to standard IHC methods and thresholds (. 50% and. 40%, respectively).MYC/BCL6/
BCL2 rearrangements were determined as previously reported.28
Abbreviations: ABC, activated B-cell–like; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; GCB, germinal center B-
cell–like; IHC, immunohistochemistry; IPI, International Prognostic Index.
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Responses were assessed by investigators using com-
puted tomography according to published criteria in
1999.18 Bone marrow biopsy was not mandatory. Adverse
events (AEs) were graded based on the National Cancer
Institute Common Terminology Criteria for Adverse Events
(version 4.03). A geriatric status assessment was per-
formed at baseline using the instrumental activities of daily
living (IADL) scale, the Cumulative Illness Rating Scale-
Geriatric (CIRSG), the Mini Nutritional Assessment
(MNA), and G8 scoring.19-21
Statistical Analysis
The primary end point was the OS. Using a one-arm
survival sample size, we designed the trial to have 80%
power to detect an increase from 59% to 74% in the 2-
year OS at the overall 5% significance level in favor of the
experimental arm, leading to the inclusion of a total of 250
patients. A Cox regression model was used to assess the
effect of prognostic factors on OS in multivariate analyses.
EFS, PFS, and OS were compared between arms using the
stratified log-rank test and Cox proportional hazards
model. Survival distribution was estimated using the
Kaplan-Meier product-limit method. CR rates were com-
pared using the 95% CI according to the Pearson-Clopper
method. All statistical analyses were performed in SAS




From August 20, 2014, to September 13, 2017, 249 pa-
tients enrolled in the study were randomly assigned at a 1:1
ratio to R-miniCHOP (n5 127) or R2-miniCHOP (n5 122).
Baseline characteristics are summarized in Table 1. A total
of 212 DLBCL were classified according to IHC (85%), of
which 55% were non-GCB and treated with R-miniCHOP
(62 of 103, 60%) and R2-miniCHOP (55 of 109, 50%). The
Lymph2CX molecular COO classification was obtained in
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FIG 1. Patient disposition. ITT, intention-to-treat; R-miniCHOP, cyclophosphamide, doxorubicin, vincristine, and
prednisone plus rituximab; R2-miniCHOP, R-miniCHOP plus lenalidomide.
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Treatment Delivery
Forty-eight (19%) patients discontinued treatment. Patient
disposition is summarized in the CONSORT diagram shown
in Figure 1. The median diagnosis-to-treatment interval
was 33 days (range, 8-89) in the R-miniCHOP arm and
35 days (range, 0-154) in the R2-miniCHOP arm (Data
Supplement).
In the safety set population (n 5 241), the six planned
cycles were delivered in 80% and 86% of patients in
R-miniCHOP and R2-miniCHOP, respectively. Seventy-
five percent of patients received $ 75% of the planned
dose of lenalidomide. Twenty (17%) patients experienced
a dose reduction, 17 (85%) of which were due to AEs. The
dose of lenalidomide decreased constantly over the six
cycles and was reduced by 25% or more in 20% of pa-
tients (Data Supplement). Twenty out of 117 (17.1%)
patients stopped permanently lenalidomide during plan-
ned treatment.
Primary Objective
With a median follow-up of 25.1 months, the ITT analysis
revealed that the primary end point of OS was not signifi-
cantly different between the two arms (HR, 0.99; 95% CI,
0.65 to 1.5; P5 .98, Fig 2). The 2-year OS was 66% (95%
CI, 56.4 to 74.0) in the R-miniCHOP arm and 65.7% (95%
CI, 55.6 to 74.1) in the R2-miniCHOP arm.
Among treated patients, 42 (34%) deaths occurred in the
R-miniCHOP arm (29 for lymphoma progression) and 43
(37%) in the R2-miniCHOP arm (24 for lymphoma progres-
sion). Causes of death are provided in the Data Supplement.
Secondary Objectives
The 2-year PFS was 56.2% (95% CI, 46.2 to 65.1) in the
R-miniCHOP group and 54.8% (95% CI, 44.6 to 63.9) in
the experimental arm. The 2-year EFS was 50.7% (95% CI,
40.8 to 59.8) in the R-miniCHOP arm and 53.1% (95% CI,
43 to 62.2) in the experimental arm. No significant dif-
ference between the standard and experimental arms was
observed regarding PFS (HR, 1.027, 95% CI, 0.7 to 1.5,
P 5 .89, Fig 2) and EFS (HR, 0.93, 95% CI, 0.65 to 1.34,
P 5 .70). The median DOR was not reached in the
R-miniCHOP arm (95% CI 40.1 to not applicable) and was
36 months (95% CI 26.3 to not applicable) in the R2-
miniCHOP (HR, 1.27, 95% CI, 0.77 to 2.07, P5 .34). The
ORR assessed by investigators at the end of treatment was
73% in the R-miniCHOP arm (95% CI, 64.6% to 80.7%)
and 82% in the R2-miniCHOP arm (95% CI, 75% to 89%).
CR/CRu was achieved in 53% of R-miniCHOP patients and
in 58% of R2-miniCHOP patients.
Safety and Toxicity
The safety population included 241 patients (124 R-mini-
CHOP and 117 R2-miniCHOP). Of these, 87 who received
R-miniCHOP (70%) and 101 who received R2-miniCHOP
(86%) displayed any-grade AE. Compared with standard
R-miniCHOP, more patients who received R2-miniCHOP
had at least one grade 3-4 AEs. The increased rate of grade
3-4 AEs with R2-miniCHOP was attributable primarily to
increased grade 3 or 4 neutropenia (32% v 18% patients,
P5 .01) with similar GCSF support usage (data not shown).
The most common grade 3-4 AEs and fatal AEs are pro-
vided in Table 2.
No deep venous thrombosis (DVT) but one pulmonary
embolism (PE) was reported in the standard arm. DVT and
PE occurred in six (5.1%) and seven patients (6%) treated
with R2-miniCHOP, respectively. Three patients with PE














40.1 (17.8 to NA)
32.1 (20.8 to 36.3)
Median survival (95% CL)




















Progression-free survival by arm-ITT set
+ Censored
















43.5 (40.4 to NA)
36 (27.8 to NA)
Median survival (95% CL)





















Overall survival by arm-ITT set
FIG 2. Progression-free survival (PFS) (A) and overall survival (OS) (B) in the intent-to-treat (ITT) population (N5 249) according to treatment
arm.
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Secondary primary malignancies (SPMs) were reported
in eight (6.5%) patients in the R-miniCHOP arm and
in 11 (9%) patients in the R2-miniCHOP arm (Data
Supplement).
Clinical Prognostic Factors
In univariate analyses, IPI score, stage, and serum albumin
and lymphocyte count were predictive of survival (Table 3).
Conversely, LDH, age (. or , 85 years), and monocyte
count were not predictive of survival. Among geriatric and
nutritional assessment tools, both an IADL score , 4 and
an MNA score , 12 were predictive of shorter survival.
Conversely, G8 and CIRSG did not correlate with survival
(Table 3 and Data Supplement). Regarding the clinical
impact of COO subtyping, Hans’ algorithm delineation was
not predictive of the outcome in the overall population or
according to treatment arm (Fig 3). Similarly, CD10 ex-
pression was not predictive of survival in the overall pop-
ulation or according to treatment arm (Data Supplement). In
contrast, in the subpopulation (n 5 154, 62%) molecularly
defined by Lymh2CX, the ABC subtype was related to an
unfavorable outcome compared with the non-ABC subtype.
However, no difference was observed in the ABC subtype
according to the treatment arm (Fig 3). In a multivariate
analysis incorporating IPI, albuminemia, IADL, lymphocyte
count, and GCB/ABC status, only albuminemia, 35 g/L was
predictive of the OS in the overall population and according
to treatment arm (Table 4).
DISCUSSION
To the best of our knowledge, we report the first randomized
phase III study dedicated to patients with DLBCL of age
TABLE 2. AEs and SAEs According to Treatment Arm
Adverse Event R-miniCHOP (n 5 124) R2-miniCHOP (n 5 117)
Total number of AEs 292 390
Any grade (patients) 87 (70%) 101 (86%)
Number of AEs per patient: median (q1-q3) 2 (0-4) 2 (1-5)
Total number of grade 3-4 AEs 216 (74%) 324 (83%)
Grade 3-4 AEs (patients) 71 (57%) 95 (81%)
Neutropenia 22 (18%) 38 (35%)
Anemia 7 (5%) 11 (9%)
Thrombocytopenia 1 (0.8%) 9 (7.6%)
Febrile neutropenia 1 (0.8%) 4 (3.4%)
Infections 10 (8%) 16 (13.5%)
DVT 0 (0%) 6 (5%)
PE 1 (0.8%) 7 (6%)
Vascular disorders (arterial) 2 (1.5%) 6 (5%)
Grade 5 (fatal) number 7 (5.6%) 8 (6.8%)
Total number of SAEs 76 113
Infections and infestations 12 (9.7%) 17 (14.5%)
Respiratory and mediastinal disorders 4 (3.2%) 13 (11.1%)
GI disorders 8 (6.5%) 6 (5.1%)
General disorders 6 (4.8%) 8 (6.8%)
Injury and procedural complications 4 (3.2%) 7 (6%)
Cardiac and vascular disorders 3 (2.4%) 6 (5.1%)
Metabolism and nutrition disorders 2 (1.6%) 4 (3.4%)
Musculoskeletal tissue disorders 1 (0.8%) 5 (4.3%)
Renal and urinary disorders 2 (1.6%) 4 (3.4%)
Nervous system disorders 2 (1.6%) 3 (2.6%)
Psychiatric disorders 2 (1.6%) 1 (0.9%)
Skin disorders 0 (0%) 1 (0.9%)
Hepatobiliary disorders 1 (0.8%) 0 (0%)
Abbreviations: AE, adverse event; DVT, deep venous thrombosis; PE, pulmonary embolism; SAE, severe adverse event.
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over 80 years. In this challenging setting, we have proven
that a large prospective study is possible. We showed no
survival advantage for the R2-miniCHOP arm compared
with the standard arm. With a median follow-up of
25 months and a 2-year OS of 66%, we replicated the
results in terms of survival at 2 years recently obtained in
LYSA trials 03-7B (59%, CI 95%, 49 to 67) and 09-7B
(64.7%, CI 95%, 55 to 73).1,2
In this trial, we failed to reject the null hypothesis. Several
explanations can be put forward to explain this result. The
proposed treatment regimen might not be adequate and
brings insufficient doses of lenalidomide to the patient. In
this category of very elderly patients, the dose of 10 mg
once daily D1-D14 (ie, 140 mg/cycle) has been proposed
and is accompanied by significant additional toxicity,
suggesting that a higher dose would probably not have
been properly tolerated. Different clinical trials have
proposed different regimens, but they involved younger
patients. In the phase III ROBUST trial for ABC DLBCLs
(median age of 65 years), lenalidomide 15 mg once
daily was combined with standard R-CHOP from D1 to
D15 (225 mg/cycle).22 In the phase II randomized
ECOG-ACRIN trial (E1412) comparing R2-CHOP and
R-CHOP, patients with DLBCL (median age, 66 years
[range, 24-92]) received lenalidomide at a dose of 25
mg once daily from D1 to D10 (250 mg/cycle) in the
experimental arm.23
Identical to our study, the ROBUST trial did not dem-
onstrate an advantage to the use of lenalidomide in
combination with RCHOP in patients with ABC DLBCL.
Overall, the ROBUST study did not meet the primary end
point of PFS for R2-CHOP versus placebo/R-CHOP.22
Conversely, the preliminary results of the ECOG-ACRIN
trial suggest an advantage in terms of PFS for the R2-
CHOP arm with significantly different rates of grade . 3
AEs between arms.23 In the SENIOR trial, we showed a
significant decrement in the planned doses of lenalido-
mide over the cycles, suggesting that we did not achieve
sufficient doses for a large number of patients who were
analyzed in ITT.
These results may suggest that the treatment regimen
proposed in the SENIOR trial was inadequate to deliver a
sufficient dose of lenalidomide. A strategy based on the use
of lenalidomide in maintenance after RCHOP had been
explored in the REMARC trial but failed to show an im-
provement of OS in patients of age 60 to 80 years.24
The toxicity of the R2 miniCHOP combination could have
strongly affected the final result of the trial. Indeed, in a
strategy based on the combination of drug X with R-CHOP
at full or reduced dose, toxicity is a major obstacle, par-
ticularly in elderly subjects. In the Phoenix trial comparing
R-CHOP versus RCHOP plus ibrutinib, the advantage of
adding ibrutinib was only observed in patients under 60
years of age. A decrease in the dose intensity of R-CHOP
was thus observed in elderly patients treated with R-CHOP
plus ibrutinib in the Phoenix trial and could explain the lack
of benefit of the combination.25 In the SENIOR trial, the very
high number of toxicities and comorbidities inherent to this
population may lead to negating the beneficial effect of the
experimental drug even if the dose intensity of R-miniCHOP
received was equivalent in both arms. The use of the
subcutaneous form of rituximab did not seem to affect the
high frequency of side effects related to R2miniCHOP, and
subcutaneous rituximab is effective and safe in very elderly
TABLE 3. Univariate analyses of prognostic factors for OS
Variable 2-Year OS HR (95% CI) Log-Rank P
IPI (0-2 v 3-5) 80.61% v 60.88% 2.26 (1.25 to 4.08) .0054
Ann Arbor stage (II-III v IV) 82.54% v 59.91% 2.12 (1.2 to 3.76) .0083
LDH (normal v . UL) 70.7% v 63.5% 1.28 (0.81 to 2.03) .2808
Hans score (non-GC v GC) 68.93% v 59.86% 1.32 (0.84 to 2.07) .2345
Nanostring (non-ABC v ABC) 74.26% v 63.11% 1.77 (1.01 to 3.11) .0438
G8 score (# 14 v . 14) 67.59% v 70.41% 0.94 (0.47 to 1.88) .8555
IADL scale (4 v , 4) 74.98% v 58.99% 1.69 (1.09 to 2.64) .0179
MNA (normal v malnourished) 63.89% v 74.58% 0.57 (0.35 to 0.94) .0245
CIRSG (, 7 v $ 7) 67.22% v 67.02% 1.12 (0.7 to 1.77) .6406
Monocyte count (# 0.7 v . 0.7 G/L) 64.82% v 66.39% 0.90 (0.59 to 1.38) .6336
Lymphocyte count (, 1 v $1 G/L) 59.06% v 69.45% 0.66 (0.43 to 1) .049
Albumin (#35 v . 35 g/L) 78.1% v 52.07% 2.51 (1.6 to 3.92) < .0001
NOTE. Bold indicates statistically significant P values.
Abbreviations: ABC, activated B-cell–like; CIRSG, Cumulative Illness Rating Scale-Geriatric; GC, Germinal Center B-cell-like; HR, hazard ratio; IADL,
instrumental activities of daily living; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MNA, mini-nutritional assessment; OS, overall survival;
UL, upper limit.
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FIG 3. Overall survival (OS) and progression-free survival (PFS) according to cell of origin (COO) status determined by immunohistochemistry (IHC)
(A-C), by Lymph2CX (D-F) in the overall population (A and D), and according to treatment arm (B, C, E, and F).
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patients with DLBCL, as previously reported in younger
patients with FL or DLBCL.26
The negative results of the study could also be due to the
unexpectedly low proportion of ABC DLBCL subtypes in
this population of very elderly patients, a subtype in which
lenalidomide is believed to be particularly effective.7
Despite stratification based on CD10 staining, only
50% were finally classified as non-GCB in the R2-
miniCHOP arm using the Hans algorithm and 42%
were classified as ABC using L2CX technology, sug-
gesting that too few ABC DLBCL may not demonstrate a
survival advantage for R2-miniCHOP. However, to date,
there is no formal evidence that lenalidomide is a par-
ticularly effective drug in patients with ABC DBCLs,
contrary to in vitro data.
The long-term follow-up of R2-CHOP21 in DLBCL was
recently reported in the merged two independent phase II
trials conducted by the Mayo clinic and FIL. A total of 112
patients with a median age of 69 years were analyzed with
a median follow-up of 5.1 years.14 The cumulative inci-
dence of primary secondary malignancies at 5 years was
0.9% for therapy-related secondary acute leukemia and/
or myelodysplastic syndromes and 5.4% for other tu-
mors. In the SENIOR trial, with a shorter follow-up of
25 months, SPMs were numerically similar between the
two arms (eight patients in the standard arm and 11
patients in the experimental arm) but seem to be qual-
itatively different.
Given the demographics of the population, improving the
effectiveness of treatment and the survival of patients over
80 years of age with DLBCL is still a major challenge in
2020. The SENIOR trial highlights and confirms a certain
number of prognostic factors that make it possible to
identify the most fragile patients for whom standard che-
motherapy based on immunochemotherapy does not seem
to be adequate, even after a prephase has been performed
in all patients.
Among these factors, albuminemia is, with staging, the
most significant factor, independent of the IPI, MNA score,
or IADL scale. These data confirm those of LYSA Trial 03-
7B and suggest that this parameter should lead to changes
in the therapeutic strategy of these high-risk patients and
lead to the development of alternative chemo-free
strategies.2
In our cohort, although Hans’ algorithm does not seem to
confirm the prognostic value of the GCB/non-GCB phe-
notype, the molecular classification carried out in a sub-
group seems to confirm the pejorative prognostic value of
the ABC phenotype. This suggests that the understanding
of the molecular specificities of DLBCL in the very elderly,
independent of the intrinsic fragility linked to the geriatric
context, is an important area for improvement in the
management of these patients.27
In conclusion, the SENIOR study is the first prospective
phase III trial in patients older than 80 years with newly
diagnosed DLBCL. The addition of lenalidomide to the
R-miniCHOP schema does not improve OS irrespective of
GCB/ABC status and results in more AEs. Rituximab
delivered subcutaneously was safe and well-tolerated in
this very elderly population, showing a similar efficacy with
historic R-miniCHOP data. In three consecutive trials
dedicated to DLBCL. 80 years, our group confirmed that
R-miniCHOP led to 2-year OS rates from 59% to 66 %.
New therapeutic strategies are needed to improve such
results.
Role of the Funding Source
This study was designed by the LYSA scientific committee.
All logistical aspects of this study were managed by the
LYSARC. Data were collected by LYSARC and analyzed by
LYSARC and the PI and Co-PI. Celgene and Roche pro-
vided lenalidomide (Revlimid) and rituximab (Mabthera),
respectively. Celgene supports the cost of NanoString ex-
periments. The PI and Co-PI were responsible for data
interpretation and writing of the report. All authors had full
access to the data in this study, and the corresponding
author had final responsibility for the decision to submit the
manuscript for publication.
TABLE 4. Multivariate Analyses of Prognostic Factors for OS
Variable HR (95% CI) P
IPI (0-2 v 3-5) 0.94 (0.43 to 2.04) .871
Non-ABC v ABC (Lymph2CX) 1.14 (0.68 to 1.92) .614
IADL scale 0.72 (0.44 to 1.18) .193
MNA (normal v malnourished) 1.16 (0.67 to 2.03) .596
Ann Arbor stage (II-III v IV) 2.01 (0.94 to 4.32) .073
Lymphocyte count (, 1 v $1 G/L) 0.80 (0.50 to 1.30) .373
Albumin (#35 v . 35 g/L) 2.08 (1.25 to 3.57) .005
NOTE. Bold indicates statistically significant P values.
Abbreviations: ABC, activated B-cell–like; HR, hazard ratio; IADL, instrumental activities of daily living; IPI, international prognostic index; MNA, Mini
Nutritional Assessment; OS, overall survival.
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5Anapath Research Unit (EA) EA4340 and Pathology Laboratory,
Versailles University and APHP, Ambroise Paré Hospital, Boulogne,
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